These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36710368)

  • 1. Mechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors.
    Weddell J
    CPT Pharmacometrics Syst Pharmacol; 2023 Nov; 12(11):1726-1737. PubMed ID: 36710368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summary of a workshop on preclinical and translational safety assessment of CD3 bispecifics.
    Kamperschroer C; Shenton J; Lebrec H; Leighton JK; Moore PA; Thomas O
    J Immunotoxicol; 2020 Dec; 17(1):67-85. PubMed ID: 32100588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity.
    Li J; Piskol R; Ybarra R; Chen YJ; Li J; Slaga D; Hristopoulos M; Clark R; Modrusan Z; Totpal K; Junttila MR; Junttila TT
    Sci Transl Med; 2019 Sep; 11(508):. PubMed ID: 31484792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Priming treatment with T-cell redirecting bispecific antibody ERY974 reduced cytokine induction without losing cytotoxic activity in vitro by changing the chromatin state in T cells.
    Iwata Y; Narushima Y; Harada A; Mishima M
    Toxicol Appl Pharmacol; 2022 Apr; 441():115986. PubMed ID: 35304238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Modeling Framework to Characterize Cytokine Release upon T-Cell-Engaging Bispecific Antibody Treatment: Methodology and Opportunities.
    Chen X; Kamperschroer C; Wong G; Xuan D
    Clin Transl Sci; 2019 Nov; 12(6):600-608. PubMed ID: 31268236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
    Skokos D; Waite JC; Haber L; Crawford A; Hermann A; Ullman E; Slim R; Godin S; Ajithdoss D; Ye X; Wang B; Wu Q; Ramos I; Pawashe A; Canova L; Vazzana K; Ram P; Herlihy E; Ahmed H; Oswald E; Golubov J; Poon P; Havel L; Chiu D; Lazo M; Provoncha K; Yu K; Kim J; Warsaw JJ; Stokes Oristian N; Siao CJ; Dudgeon D; Huang T; Potocky T; Martin J; MacDonald D; Oyejide A; Rafique A; Poueymirou W; Kirshner JR; Smith E; Olson W; Lin J; Thurston G; Sleeman MA; Murphy AJ; Yancopoulos GD
    Sci Transl Med; 2020 Jan; 12(525):. PubMed ID: 31915305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART
    Betts A; Haddish-Berhane N; Shah DK; van der Graaf PH; Barletta F; King L; Clark T; Kamperschroer C; Root A; Hooper A; Chen X
    AAPS J; 2019 May; 21(4):66. PubMed ID: 31119428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational Analysis of Cytokine Release Following Bispecific T-Cell Engager Therapy: Applications of a Logic-Based Model.
    Selvaggio G; Parolo S; Bora P; Leonardelli L; Harrold J; Mehta K; Rock DA; Marchetti L
    Front Oncol; 2022; 12():818641. PubMed ID: 35350575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daily ascending dosing in cynomolgus monkeys to mitigate cytokine release syndrome induced by ERY22, surrogate for T-cell redirecting bispecific antibody ERY974 for cancer immunotherapy.
    Iwata Y; Sasaki M; Harada A; Taketo J; Hara T; Akai S; Ishiguro T; Narita A; Kaneko A; Mishima M
    Toxicol Appl Pharmacol; 2019 Sep; 379():114657. PubMed ID: 31326447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a minimal physiologically-based pharmacokinetic/pharmacodynamic model to characterize target cell depletion and cytokine release for T cell-redirecting bispecific agents in humans.
    Jiang X; Chen X; Jaiprasart P; Carpenter TJ; Zhou R; Wang W
    Eur J Pharm Sci; 2020 Apr; 146():105260. PubMed ID: 32058058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
    Martin TG; Mateos MV; Nooka A; Banerjee A; Kobos R; Pei L; Qi M; Verona R; Doyle M; Smit J; Sun W; Trancucci D; Uhlar C; van de Donk NWCJ; Rodriguez C
    Cancer; 2023 Jul; 129(13):2035-2046. PubMed ID: 36991547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.
    Leclercq G; Haegel H; Schneider A; Giusti AM; Marrer-Berger E; Boetsch C; Walz AC; Pulko V; Sam J; Challier J; Ferlini C; Odermatt A; Umaña P; Bacac M; Klein C
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors.
    Harding JJ; Garrido-Laguna I; Chen X; Basu C; Dowlati A; Forgie A; Hooper AT; Kamperschroer C; Max SI; Moreau A; Shannon M; Wong GY; Hong DS
    Front Immunol; 2022; 13():845417. PubMed ID: 35493516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of bispecific T cell engagers: harnessing quantitative systems pharmacology.
    Qi T; Liao X; Cao Y
    Trends Pharmacol Sci; 2023 Dec; 44(12):880-890. PubMed ID: 37852906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release.
    Dang K; Castello G; Clarke SC; Li Y; Balasubramani A; Boudreau A; Davison L; Harris KE; Pham D; Sankaran P; Ugamraj HS; Deng R; Kwek S; Starzinski A; Iyer S; van Schooten W; Schellenberger U; Sun W; Trinklein ND; Buelow R; Buelow B; Fong L; Dalvi P
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp.
    Hassel JC; Berking C; Forschner A; Gebhardt C; Heinzerling L; Meier F; Ochsenreither S; Siveke J; Hauschild A; Schadendorf D
    Eur J Cancer; 2023 Sep; 191():112986. PubMed ID: 37595494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors.
    Liu AW; Wei AZ; Maniar AB; Carvajal RD
    Expert Opin Biol Ther; 2022 Aug; 22(8):997-1004. PubMed ID: 35060440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
    Ishiguro T; Sano Y; Komatsu SI; Kamata-Sakurai M; Kaneko A; Kinoshita Y; Shiraiwa H; Azuma Y; Tsunenari T; Kayukawa Y; Sonobe Y; Ono N; Sakata K; Fujii T; Miyazaki Y; Noguchi M; Endo M; Harada A; Frings W; Fujii E; Nanba E; Narita A; Sakamoto A; Wakabayashi T; Konishi H; Segawa H; Igawa T; Tsushima T; Mutoh H; Nishito Y; Takahashi M; Stewart L; ElGabry E; Kawabe Y; Ishigai M; Chiba S; Aoki M; Hattori K; Nezu J
    Sci Transl Med; 2017 Oct; 9(410):. PubMed ID: 28978751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonclinical Investigation of Cytokine Mitigation Strategies for T-cell-Engaging Bispecifics in the Cynomolgus Macaque.
    Kamperschroer C; Guffroy M; Shen A; Dokmanovich M; Stubbs M; O'Donnell LM
    J Immunother; 2024 Jun; 47(5):160-171. PubMed ID: 38562119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuning the potency and selectivity of ImmTAC molecules by affinity modulation.
    Robertson IB; Mulvaney R; Dieckmann N; Vantellini A; Canestraro M; Amicarella F; O'Dwyer R; Cole DK; Harper S; Dushek O; Kirk P
    Clin Exp Immunol; 2024 Feb; 215(2):105-119. PubMed ID: 37930865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.